Edwards Lifesciences (NYSE:EW) VP Donald Bobo, Jr. Sells 11,340 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $1.69 on Tuesday, hitting $85.86. 3,811,822 shares of the company traded hands, compared to its average volume of 3,465,341. The firm’s 50-day simple moving average is $84.87 and its 200 day simple moving average is $80.10. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company has a market cap of $49.82 billion, a P/E ratio of 37.01, a P/E/G ratio of 3.47 and a beta of 0.95. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. The firm’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Stifel Nicolaus set a $100.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.05.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.5% during the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after purchasing an additional 365,581 shares during the period. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 4.9% in the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares during the period. Bank of New York Mellon Corp lifted its holdings in Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after buying an additional 1,423,365 shares during the period. Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 19.6% in the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after buying an additional 2,287,783 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after buying an additional 45,555 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.